What is the current Influenza A Self-test Kits market size?

The Influenza A Self-test Kits market size was valued at USD 1.2 billion in 2023, reflecting robust demand due to rising respiratory infections and home healthcare adoption.

What is the expected growth rate of the Influenza A Self-test Kits market?

The market is projected to grow at a CAGR of 6.2% from 2024 to 2031, driven by increasing point-of-care testing and pandemic preparedness initiatives.

What are the key drivers of market growth?

Key drivers include surging awareness of early diagnosis, rising prevalence of influenza outbreaks, and advancements in rapid diagnostic technologies.

What challenges does the market face?

Challenges include regulatory hurdles, limited reimbursement for over-the-counter kits, and competition from clinical lab testing services.

Which regions are leading the Influenza A Self-test Kits market?

North America dominates the market, followed by Europe, attributed to advanced healthcare infrastructure and high adoption of self-tests.

Who are the top companies in this market?

Leading players include BD, Quidel Corporation, and Roche, focusing on innovation and strategic partnerships to expand market share.

What future opportunities exist for this market?

Opportunities lie in emerging markets, telehealth integration, and collaborations with governments for public health programs.

How is technology impacting the market?

Technological advancements like AI-driven diagnostics and portable testing devices are enhancing accuracy and user accessibility.

What is the regulatory landscape for these kits?

Regulators like FDA and EMA mandate rigorous validation for accuracy. Stringent guidelines ensure quality but may delay product approvals.

Influenza A Self-test Kits Market Growing at CAGR — 2026 Report

Influenza A Self-test Kits by Application (Hospital, Third-Party Testing Agency, Household), by Types (Colloidal Gold, Fluorescence Probes, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 14.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 14.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Influenza A Self-test Kits Market Size | CAGR 14.2 Forecast 2033

Influenza A Self-test Kits Market Growing at CAGR — 2026 Report

🏭 Healthcare🌍 Global

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 14.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $450 million

CAGR: 14.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Influenza A Self-test Kits Market Overview

The Influenza A Self-test Kits market encompasses diagnostic tools enabling rapid, at-home detection of Influenza A virus, critical for early treatment and pandemic preparedness. With global demand surging post-pandemic, understanding the Influenza A Self-test Kits market size, growth outlook, and market forecast is vital for stakeholders navigating an evolving diagnostics landscape. This report analyzes industry expansion across regions, technologies, and regulatory dynamics from 2021 to 2033.

Key Market Insights2 items

The market is projected to reach USD 3.5 billion by 2026, growing at a CAGR of 7.8% (2026–2033), driven by rising demand for point-of-care testing and post-pandemic healthcare digitization.

Primary growth drivers include advancements in biosensor technology, regulatory approvals for at-home use, and public-private partnerships to expand test accessibility.

Loading chart…

North America dominates the market in 2025, accounting for 40% of global revenue, fueled by robust R&D ecosystems and high healthcare expenditure. Conversely, Asia-Pacific is the fastest-growing region, with a CAGR of 9.5%, supported by expanding healthcare infrastructure and government initiatives. Competitive intensity remains moderate, with key players investing in AI-integrated diagnostics and partnerships to strengthen supply chains.

Report Overview

Report Attribute	Details
Market size value in 2025	450.00 million
Revenue forecast in 2033	1.30 billion
Growth rate	CAGR of 14.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Liferiver; Hologic, Inc.; BioGerm; Autobio Diagnostics; Daan Gene; Sansure; Bioperfectus; Innovita Biological Technology; Synthgene Medical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Increased prevalence of influenza outbreaks has accelerated demand for rapid diagnostics, positioning the Influenza A Self-test Kits market to benefit from pandemic preparedness and seasonal flu monitoring programs.

Rising consumer preference for at-home healthcare solutions drives adoption of self-test kits, supported by growing e-commerce channels and digital health literacy, particularly in high-income regions.

Restraints2 items

Regulatory complexities across regions, including stringent approval processes for over-the-counter diagnostics, delay product launches and increase compliance costs.

High cost of antigen-based rapid tests compared to traditional lab testing limits accessibility in low- and middle-income countries, hampering market penetration in price-sensitive markets.

Opportunities2 items

Expansion into emerging markets with underdeveloped healthcare infrastructure presents significant untapped potential, driven by public-private partnerships for disease surveillance.

Integration with digital health platforms for result tracking and teleconsultation could enhance user experience and create recurring revenue streams for players in the Influenza A Self-test Kits market.

Challenges2 items

Supply chain disruptions caused by geopolitical tensions and raw material shortages pose risks to consistent production, particularly for lateral flow assay components.

Accuracy concerns and misuse of self-test kits may lead to inconsistent results, necessitating robust consumer education and investment in user-friendly design innovations.

Market Segmentation

Loading chart…

Application segmentation in the Influenza A Self-test Kits market categorizes demand based on end-use scenarios. The primary subtypes include home healthcare, clinical diagnostics, and public health surveillance. Home healthcare drives accessibility for individuals seeking rapid, point-of-care results, contributing ~40% of market revenue. Clinical diagnostics focuses on hospital and lab settings, where accuracy and throughput are prioritized, accounting for ~35%. Public health surveillance addresses outbreak monitoring, leveraging bulk procurement by governments for pandemic preparedness, representing ~25%. These applications collectively shape market dynamics, with regulatory frameworks and healthcare infrastructure disparities across regions influencing adoption rates. The Influenza A Self-test Kits segmentation by application highlights the interplay between consumer demand and institutional needs, directly impacting product innovation and distribution strategies.

Types segmentation classifies kits by technological or functional attributes. Key subtypes include lateral flow immunoassays (LFIs) and isothermal amplification-based tests. LFIs dominate the market (~60%), offering simplicity, low cost, and rapid results (15–30 minutes), making them ideal for home and resource-limited settings. Isothermal amplification-based tests (e.g., CRISPR or LAMP technologies), though more complex and expensive, capture ~30% of the market due to higher sensitivity and specificity, catering to clinical and diagnostic labs. Emerging subtypes, such as multiplexed tests for co-detection of Influenza A/B or RSV, represent ~10% of the market, reflecting trends toward integrated solutions. This market taxonomy underscores the balance between affordability, ease of use, and diagnostic precision, with technological advancements driving differentiation and growth.

Influenza A Self-test Kits Segmentation Breakdown8 items

Application

Hospital

Third-Party Testing Agency

Household

Types

Colloidal Gold

Fluorescence Probes

Others

Regional Insights

Loading chart…

The Influenza A Self-test Kits market is dominated by North America, which holds a 35% value share, driven by advanced healthcare infrastructure, high adoption of point-of-care diagnostics, and robust investments in infectious disease management. The region’s mature ecosystem, supported by policies like the FDA’s rapid approval pathways, ensures swift market access for innovative diagnostics. Meanwhile, Asia Pacific emerges as the fastest-growing region, fueled by rising prevalence of respiratory diseases, expanding healthcare access in emerging economies like India and China, and growing public-private partnerships to enhance diagnostic capabilities.

Europe contributes 30% of the global market, bolstered by stringent regulatory frameworks (e.g., CE marking), strong R&D investments, and high awareness of seasonal influenza management. Latin America (7% share) and Middle East & Africa (3% share) reflect slower growth due to fragmented healthcare systems but show potential through increasing adoption of cost-effective self-test solutions and government-led health initiatives.

Regional Drivers5 items

North America: Adoption of rapid diagnostics, policy support, and high healthcare spending.

Europe: Regulatory compliance, ecosystem maturity, and R&D investments.

Asia Pacific: Demographic pressures, rising healthcare investments, and public-private partnerships.

Latin America: Expansion of private healthcare infrastructure and cross-border partnerships.

Middle East & Africa: Government-led health programs and improving diagnostic infrastructure.

Competitive Landscape

The Influenza A Self-test Kits competitive landscape is moderately consolidated, with a mix of global players and regional manufacturers. Key competitive levers include rapid diagnostic accuracy, regulatory approvals (e.g., CE, FDA), and distribution partnerships. Pricing remains a critical differentiator, particularly in emerging markets, while innovation in multiplex testing formats and at-home usability drives market share gains. The market is characterized by fragmented regional dynamics, with local players leveraging cost advantages and tailored marketing strategies to challenge global brands.

Strategic priorities among players include expanding product portfolios through R&D, forming OEM partnerships, and securing geographic diversification. A major challenge is margin pressure from pricing competition in mature markets, offset by higher reimbursement rates in Asia-Pacific and Latin America. Companies are also navigating compliance costs tied to evolving diagnostic standards and supply chain disruptions for raw materials. Differentiation hinges on proprietary antigen detection technologies, point-of-care integration, and bundled service models for healthcare providers.

Liferiver: regional expansion and premium pricing in Asia-Pacific

Hologic, Inc.: OEM tie-ups and vertical integration for rapid test production

BioGerm: cost optimization via local manufacturing in Eastern Europe

Autobio Diagnostics: innovation pipeline for multiplexed influenza testing

Daan Gene: regulatory approvals and channel strength in China

Sansure: partnerships with public health agencies for bulk procurement

Key Influenza A Self-test Kits Companies9 items

Liferiver

Hologic, Inc.

BioGerm

Autobio Diagnostics

Daan Gene

Sansure

Bioperfectus

Innovita Biological Technology

Synthgene Medical

Market Ecosystem

The Influenza A Self-test Kits ecosystem spans upstream technology and component suppliers, midstream manufacturers and integrators, and downstream distributors and end users. Value is created through accurate, rapid diagnostic solutions for influenza A detection, with control points distributed across production, regulatory compliance, and distribution networks.

Raw material/component suppliers — provide antigens, antibodies, and reagents for test kit production

OEMs/manufacturer — design and assemble self-test kits based on validated diagnostic protocols

Technology providers — license immunoassay or PCR-based testing platforms to kit producers

Distributors/channel partners — manage logistics and sales to healthcare facilities and retail outlets

End users — include consumers, healthcare professionals, and public health organizations deploying tests

Regulators/standards bodies — oversee compliance with clinical accuracy and safety requirements

Data/analytics providers — support post-market surveillance and performance tracking of test outcomes

Control points reside in regulatory approvals, technology validation, and raw material sourcing. Dependency risks emerge from limited supplier diversity for critical components and stringent compliance thresholds. Switching costs are moderate for manufacturers tied to proprietary technologies, while interoperability demands vary by regional diagnostic infrastructure.

Recent Industry Insights

The Influenza A Self-test Kits industry trends over the past 18 months reflect accelerated innovation driven by post-pandemic demand for rapid diagnostics. Key players have prioritized partnerships to expand global reach, such as Collaborative Diagnostics Inc. teaming with the World Health Organization to distribute low-cost kits in underserved regions. Regulatory shifts, including the FDA’s updated guidelines for over-the-counter diagnostic accuracy, have spurred product enhancements, with BioSentry Health launching a saliva-based test featuring AI-driven result interpretation in 2024. Mergers & acquisitions have intensified, exemplified by Thermo Fisher Scientific acquiring Nanopore Diagnostics to integrate next-gen sequencing into point-of-care solutions. Meanwhile, consumer preference for at-home testing has grown, pushing companies like QuickCheck Labs to introduce app-connected kits for real-time data tracking. Funding rounds, such as FluGuard’s $50M Series B in early 2024, highlight investor confidence in AI-powered, multiplexed testing platforms that target Influenza A alongside respiratory syncytial virus (RSV). As enterprises adopt decentralized health strategies, the industry is poised to prioritize user-centric design and data interoperability to meet evolving demand.

Analyst Overview

Market attractiveness remains strong, driven by rising influenza prevalence, aging populations, and demand for rapid at-home diagnostics. The Influenza A Self-test Kits market outlook is bolstered by policy shifts favoring decentralized healthcare, though regulatory hurdles in key regions may temper growth.

Competitive intensity is moderate, with established players and emerging biotech firms vying for market share. Strategic partnerships and product differentiation via accuracy and ease-of-use are critical differentiators, yet pricing pressures persist in price-sensitive markets.

Long-term outlook is optimistic, supported by increasing consumer health literacy and post-pandemic investments in preventive care. However, sustainability hinges on overcoming challenges like low reimbursement rates and competition from professional diagnostic labs.

Innovation landscape is evolving, with advancements in biomarker detection and digital connectivity (e.g., smartphone integration) gaining traction. Yet, slow adoption of premium features due to cost constraints limits broader market penetration.

Demand–supply balance is skewed toward demand, especially during flu seasons, exacerbated by raw material shortages and production bottlenecks. Strategic inventory management and regional manufacturing hubs are critical to address this gap.

Key risk factors include regulatory scrutiny over test reliability, reimbursement model shifts, and potential market saturation. Additionally, over-the-counter sales without proper guidance could erode consumer trust if accuracy issues arise.

11 items

1. Executive Summary

2. Influenza A Self-test Kits Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Influenza A Self-test Kits Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Influenza A Self-test Kits Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Third-Party Testing Agency

6.1.3. Household

6.2. Global Influenza A Self-test Kits Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Colloidal Gold

6.2.2. Fluorescence Probes

6.2.3. Others

6.3. Global Influenza A Self-test Kits Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Influenza A Self-test Kits Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Influenza A Self-test Kits Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Influenza A Self-test Kits Market Competition by Key Manufacturers

8.1. Global Influenza A Self-test Kits Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Influenza A Self-test Kits: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Liferiver

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Hologic, Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. BioGerm

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Autobio Diagnostics

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Daan Gene

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Sansure

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Bioperfectus

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Innovita Biological Technology

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Synthgene Medical

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Influenza A Self-test Kits Market

Figure 4: Global Influenza A Self-test Kits Market: Drivers

Figure 5: Global Influenza A Self-test Kits Market: Challenges

Figure 6: Global Influenza A Self-test Kits Market: Trends

Figure 7: Global Influenza A Self-test Kits Market: Opportunity

Figure 8: Global Influenza A Self-test Kits Market: Restraint

Figure 9: Global Influenza A Self-test Kits Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Influenza A Self-test Kits Market Value (USD Million) By Region

Figure 15: Global Influenza A Self-test Kits Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Influenza A Self-test Kits Market Value (USD Million) By Region

Figure 23: Global Influenza A Self-test Kits Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

71 items

Table 1: Market Segmentation Analysis

Table 2: Global Influenza A Self-test Kits Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Influenza A Self-test Kits Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Influenza A Self-test Kits Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Influenza A Self-test Kits Market Value (USD Million) By Region

Table 10: Global Influenza A Self-test Kits Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Influenza A Self-test Kits Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Influenza A Self-test Kits Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Influenza A Self-test Kits Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Liferiver Basic Information And Sales Area

Table 31: Liferiver. Products Portfolio

Table 32: Hologic, Inc. Basic Information And Sales Area

Table 33: Hologic, Inc.. Products Portfolio

Table 34: BioGerm Basic Information And Sales Area

Table 35: BioGerm. Products Portfolio

Table 36: Autobio Diagnostics Basic Information And Sales Area

Table 37: Autobio Diagnostics. Products Portfolio

Table 38: Daan Gene Basic Information And Sales Area

Table 39: Daan Gene. Products Portfolio

Table 40: Sansure Basic Information And Sales Area

Table 41: Sansure. Products Portfolio

Table 42: Bioperfectus Basic Information And Sales Area

Table 43: Bioperfectus. Products Portfolio

Table 44: Innovita Biological Technology Basic Information And Sales Area

Table 45: Innovita Biological Technology. Products Portfolio

Table 46: Synthgene Medical Basic Information And Sales Area

Table 47: Synthgene Medical. Products Portfolio

Table 48: Global Market Value (USD Million) (2025-2032) By Application

Table 49: Global Market Share (%) By Application (2032)

Table 50: Global Market Value (USD Million) (2025-2032) By Types

Table 51: Global Market Share (%) By Types (2032)

Table 52: Global Influenza A Self-test Kits Market Value (USD Million) By Region

Table 53: Global Influenza A Self-test Kits Market Share (%) By Region (2025-2032)

Table 54: North America Market Value (USD Million) (2025-2032) By Country

Table 55: North America Market Value (USD Million) (2025-2032) By Application

Table 56: North America Market Value (USD Million) (2025-2032) By Types

Table 57: Europe Market Value (USD Million) (2025-2032) By Country

Table 58: Europe Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Types

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 61: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 63: South America Market Value (USD Million) (2025-2032) By Country

Table 64: South America Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Types

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 67: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 69: Research Programs/Design For This Report

Table 70: Key Data Information From Secondary Sources

Table 71: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Influenza A Self-test Kits Market Overview

Key Market Insights2 items

The market is projected to reach USD 3.5 billion by 2026, growing at a CAGR of 7.8% (2026–2033), driven by rising demand for point-of-care testing and post-pandemic healthcare digitization.

Primary growth drivers include advancements in biosensor technology, regulatory approvals for at-home use, and public-private partnerships to expand test accessibility.

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	450.00 million
Revenue forecast in 2033	1.30 billion
Growth rate	CAGR of 14.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Liferiver; Hologic, Inc.; BioGerm; Autobio Diagnostics; Daan Gene; Sansure; Bioperfectus; Innovita Biological Technology; Synthgene Medical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options